JP7536004B2 - 可溶性細胞外マトリックス組成物および血管内送達のための方法 - Google Patents

可溶性細胞外マトリックス組成物および血管内送達のための方法 Download PDF

Info

Publication number
JP7536004B2
JP7536004B2 JP2021521511A JP2021521511A JP7536004B2 JP 7536004 B2 JP7536004 B2 JP 7536004B2 JP 2021521511 A JP2021521511 A JP 2021521511A JP 2021521511 A JP2021521511 A JP 2021521511A JP 7536004 B2 JP7536004 B2 JP 7536004B2
Authority
JP
Japan
Prior art keywords
composition
soluble
ecm
pharmaceutical composition
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505468A (ja
JP2022505468A5 (https=
JPWO2020086955A5 (https=
Inventor
クリストマン，カレン
スパング，マーティン
グローバー，グレゴリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022505468A publication Critical patent/JP2022505468A/ja
Publication of JP2022505468A5 publication Critical patent/JP2022505468A5/ja
Publication of JPWO2020086955A5 publication Critical patent/JPWO2020086955A5/ja
Priority to JP2024129889A priority Critical patent/JP2024166198A/ja
Application granted granted Critical
Publication of JP7536004B2 publication Critical patent/JP7536004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021521511A 2018-10-25 2019-10-25 可溶性細胞外マトリックス組成物および血管内送達のための方法 Active JP7536004B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024129889A JP2024166198A (ja) 2018-10-25 2024-08-06 可溶性細胞外マトリックス組成物および血管内送達のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862750303P 2018-10-25 2018-10-25
US62/750,303 2018-10-25
PCT/US2019/058052 WO2020086955A1 (en) 2018-10-25 2019-10-25 Soluble extracellular matrix composition and method for intravascular delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024129889A Division JP2024166198A (ja) 2018-10-25 2024-08-06 可溶性細胞外マトリックス組成物および血管内送達のための方法

Publications (4)

Publication Number Publication Date
JP2022505468A JP2022505468A (ja) 2022-01-14
JP2022505468A5 JP2022505468A5 (https=) 2022-08-19
JPWO2020086955A5 JPWO2020086955A5 (https=) 2022-08-19
JP7536004B2 true JP7536004B2 (ja) 2024-08-19

Family

ID=70330739

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521511A Active JP7536004B2 (ja) 2018-10-25 2019-10-25 可溶性細胞外マトリックス組成物および血管内送達のための方法
JP2024129889A Pending JP2024166198A (ja) 2018-10-25 2024-08-06 可溶性細胞外マトリックス組成物および血管内送達のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024129889A Pending JP2024166198A (ja) 2018-10-25 2024-08-06 可溶性細胞外マトリックス組成物および血管内送達のための方法

Country Status (7)

Country Link
US (1) US20210379245A1 (https=)
EP (1) EP3870192A4 (https=)
JP (2) JP7536004B2 (https=)
CN (1) CN112867499A (https=)
AU (1) AU2019363610B2 (https=)
CA (1) CA3117688A1 (https=)
WO (1) WO2020086955A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364152A1 (en) * 2020-09-14 2023-11-16 The Regents Of The University Of California Compositions and methods of use for infusible extracellular matrix
CN121195059A (zh) * 2023-04-06 2025-12-23 株式会社Medifab 基于超临界二氧化碳工艺的水溶性脱细胞基质

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536246A (ja) 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓治療のための組成物及び方法
KR101628821B1 (ko) 2015-03-02 2016-06-13 강원대학교산학협력단 탈세포화된 생체 조직 유래의 생체적합성 가용화 스캐폴드 추출물, 이의 제조방법 및 이의 용도
WO2018161034A1 (en) 2017-03-02 2018-09-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Extracellular matrix (ecm) hydrogel and soluble fraction thereof for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164728A1 (en) * 2014-04-24 2015-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fractionating extracellular matrix to modulate bioactivity and the host response
US11406736B2 (en) * 2016-01-13 2022-08-09 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Vascular extracellular matrix hydrogel
EP3755267B1 (en) * 2018-02-22 2024-06-12 University of Pittsburgh - of the Commonwealth System of Higher Education Extracts for the regeneration of ligaments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536246A (ja) 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓治療のための組成物及び方法
KR101628821B1 (ko) 2015-03-02 2016-06-13 강원대학교산학협력단 탈세포화된 생체 조직 유래의 생체적합성 가용화 스캐폴드 추출물, 이의 제조방법 및 이의 용도
WO2018161034A1 (en) 2017-03-02 2018-09-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Extracellular matrix (ecm) hydrogel and soluble fraction thereof for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SINGELYN J. M. et al.，Journal of American College of Cardiology，2012年，Vol.59 No.8，pp.751-763

Also Published As

Publication number Publication date
AU2019363610B2 (en) 2025-11-13
WO2020086955A1 (en) 2020-04-30
EP3870192A1 (en) 2021-09-01
AU2019363610A1 (en) 2021-05-13
US20210379245A1 (en) 2021-12-09
CA3117688A1 (en) 2020-04-30
EP3870192A4 (en) 2022-09-21
JP2024166198A (ja) 2024-11-28
JP2022505468A (ja) 2022-01-14
CN112867499A (zh) 2021-05-28

Similar Documents

Publication Publication Date Title
US11648281B2 (en) Methods for treating cardiac conditions
JP2024166198A (ja) 可溶性細胞外マトリックス組成物および血管内送達のための方法
Nguyen et al. Developing injectable nanomaterials to repair the heart
KR20120100962A (ko) 신장 손상을 치료하는데 사용하기 위한 조혈 줄기 세포
US20230129268A1 (en) Platelet rich plasma formulations
Zhu et al. Peripheral nerve defects repaired with autogenous vein grafts filled with platelet-rich plasma and active nerve microtissues and evaluated by novel multimodal ultrasound techniques
JP7554033B2 (ja) 組織病変治療用組成物
Yu et al. Mesenchymal stem cell secretome-loaded fibrin glue improves the healing of intestinal anastomosis
Kanemitsu et al. Insulin-like growth factor-1 enhances the efficacy of myoblast transplantation with its multiple functions in the chronic myocardial infarction rat model
US20220395558A1 (en) Compositions for treatment of erectile dysfunction, methods for preparing the same and applications thereof
CN101229366B (zh) 成纤维细胞生长因子在制备促进血管生成药物中的应用
Mourão et al. The use of Alb-PRF as a drug delivery system for malignant lesion treatment
US20150283183A1 (en) Methods for treating cardiac conditions
Patil et al. Hydrogel-based therapies for cardiovascular diseases
US20230364152A1 (en) Compositions and methods of use for infusible extracellular matrix
Spang Intravascular infusion of a soluble extracellular matrix hydrogel therapy for acute myocardial infarction
CN121648162A (zh) 一种心功能制剂及其制备方法和应用
EP4622653A1 (en) Compositions based on a mixture of bioactive molecules and exosomes for use in the treatment of conditions requiring tissue repair and regeneration
Pascual-Gil Nuevas estrategias para la reparación cardiaca basadas en sistemas de liberación poliméricos y factores de crecimiento
de Abreu OliveiraI et al. Vascular endothelial growth factor association with angiopoietin 1 promotes improvement in ventricular function after ischemic cardiomyopathy induced in mini pigs1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230719

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240806

R150 Certificate of patent or registration of utility model

Ref document number: 7536004

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150